Cart
sales@molnova.com
PPY A
CAS No. 875634-01-8
PPY A( —— )
Catalog No. M33910 CAS No. 875634-01-8
PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinase (IC50 of 9 and 20 nM, respectively).PPY A also inhibits the growth of Bcr-Abl T315l mutant or wild-type Bcr-Abl genetically transformed cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 240 | Get Quote |
|
| 5MG | 375 | Get Quote |
|
| 10MG | 615 | Get Quote |
|
| 25MG | 902 | Get Quote |
|
| 50MG | 1224 | Get Quote |
|
| 100MG | 1611 | Get Quote |
|
| 500MG | 3267 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePPY A
-
NoteResearch use only, not for human use.
-
Brief DescriptionPPY A is a potent inhibitor of T315l mutant and wild-type Abl kinase (IC50 of 9 and 20 nM, respectively).PPY A also inhibits the growth of Bcr-Abl T315l mutant or wild-type Bcr-Abl genetically transformed cells.
-
DescriptionPPY-A is a potent T315I mutant and wild-type Abl kinases inhibitor with IC50s of 9 and 20 nM, respectively. PPY-A inhibits Ba F3 cells transformed with wild-type Abl and Abl T315I mutantl with IC50s of 390 and 180 nM, respectively. PPY-A can be used for the research of chronic myeloid leukemia (CML).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetBcr-Abl
-
RecptorBcr-Abl
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number875634-01-8
-
Formula Weight372.42
-
Molecular FormulaC22H20N4O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(C1=CN=CC(=C1)C2=CN=C3NC=C(C=4C=CC=CC4OC)C3=C2)N(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tianjun Zhou, et al. Crystal structure of the T315I mutant of AbI kinase. Chem Biol Drug Des. 2007 Sep;70(3):171-81.?
molnova catalog
related products
-
Lyn-IN-1
Lyn-IN-1 is a potent and selective dual Bcr-Abl/Lyn inhibitor.
-
GNF-2
A potent, allosteric, non-ATP competitive Bcr-Abl inhibitor that shows exclusive antiproliferative activity toward Bcr-abl-transformed cells.
-
Dasatinib hydrochlor...
A potent, orally bioavailable, dual Src/Abl kinase inhibitor with IC50 of 0.5, 0.4, 0.5 and <1 nM for Src, Lck, Yes and Bcr-Abl, respectively.
